B cell immunofocusing and repriming in two HIV-1 Env immunization regimens.

Autor:	DeLuca JM; Translational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Blasi M; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA., Jha S; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Surgery, Duke University, Durham, NC, USA., Shen X; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Surgery, Duke University, Durham, NC, USA., Pollara J; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Surgery, Duke University, Durham, NC, USA., Kerkau M; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Surgery, Duke University, Durham, NC, USA., Purwar M; Wistar Institute, Philadelphia, PA, USA., Carnathan DG; Emory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA., Negri D; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy., Cara A; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.; National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy., Wollenberg K; Bioinformatics & Computational Biosciences Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Saunders KO; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Surgery, Duke University, Durham, NC, USA., Lu S; University of Massachusetts Medical School, Worcester, MA, USA., Silvestri G; Emory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA., Weiner DB; Wistar Institute, Philadelphia, PA, USA., Klotman ME; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA., Ferrari G; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Surgery, Duke University, Durham, NC, USA., Moody MA; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Pediatrics, Duke University, Durham, NC, USA., Bonsignori M; Translational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jazyk:	angličtina
Zdroj:	Research square [Res Sq] 2024 Apr 08. Date of Electronic Publication: 2024 Apr 08.
DOI:	10.21203/rs.3.rs-3895128/v1
Abstrakt:	Diverse and rapidly mutating viruses pose challenges to immunogen and vaccine design. In this study, we evaluated the ability of memory B-cells obtained from two independent NHP trials to cross-react with individual HIV-1 vaccine components of two different multivalent immunization strategies. We demonstrated that while an HIV-1 Env multiclade, multivalent immunization regimen resulted in a dominant memory B-cell response that converged toward shared epitopes, in a sequential immunization with clonally-related non-stabilized gp140 HIV-1 Envs followed by SOSIP-stabilized gp140 trimers, the change in immunogen format resulted in repriming of the B-cell response. Competing Interests: Additional Declarations: There is NO Competing Interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu